🇺🇸 FDA

Company profile · Sponsor

Trevi

Trevi Therapeutics

TRVI · NYSE pharma NEW HAVEN, CT, USA
Pipeline
11
Drugs
0
Patents
7

Quick answer

Trevi (TRVI) is a pharma company. headquartered in NEW HAVEN, CT, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker TRVI
Exchange NYSE
Company type pharma
Headquarters NEW HAVEN, CT, USA
SEC CIK 0001563880

Pipeline (11)

Search pipeline →

  1. Nalbuphine ER Tablets

    Trevi

    Prurigo Nodularis

    phase 3 small molecule completed

    1 trial

  2. nalbuphine HCl ER

    Trevi

    Prurigo Nodularis

    phase 3 small molecule completed

    1 trial

  3. nalbuphine HCl ER

    Trevi

    Uremic Pruritus

    phase 3 small molecule completed

    2 trials

  4. nalbuphine HCl ER tablets 60 mg BID

    Trevi

    Uremic Pruritus

    phase 3 small molecule completed

    1 trial

  5. nalbuphine HCl ER tablets 90 mg BID

    Trevi

    Prurigo Nodularis

    phase 3 small molecule completed

    1 trial

  6. NAL ER

    Trevi

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  7. NAL ER

    Trevi

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    3 trials

  8. Nalbuphine ER, Placebo - Nalbuphine ER, Nalbuphine ER

    Trevi

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  9. NAL ER

    Trevi

    Healthy Participants

    phase 1 small molecule active

    2 trials

  10. Nalbuphine ER

    Trevi

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  11. Nalbuphine HCl solution

    Trevi

    Nalbuphine

    phase 1 small molecule completed

    1 trial

Patents (7)

Search patents →

  1. US 12274696

    Methods of administering nalbuphine

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11660296

    Treatment of chronic cough, breathlessness and dyspnea

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10238646

    Methods for treating pruritus

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9624233

    Compounds for treating pruritic conditions

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8987289

    Methods for treating pruritus

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8940753

    Methods for treating pruritis

    Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8637538

    Methods for treatment of pruritis

    Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Trevi?

Trevi (TRVI) is a pharma company. headquartered in NEW HAVEN, CT, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does Trevi sponsor?

We track 11 ClinicalTrials.gov-linked programs for Trevi, including Nalbuphine ER Tablets and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Trevi company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.